PE20080432A1 - CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Google Patents

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Info

Publication number
PE20080432A1
PE20080432A1 PE2007000999A PE2007000999A PE20080432A1 PE 20080432 A1 PE20080432 A1 PE 20080432A1 PE 2007000999 A PE2007000999 A PE 2007000999A PE 2007000999 A PE2007000999 A PE 2007000999A PE 20080432 A1 PE20080432 A1 PE 20080432A1
Authority
PE
Peru
Prior art keywords
pyridyl
amino
substituted
phenyl
compositions
Prior art date
Application number
PE2007000999A
Other languages
Spanish (es)
Inventor
Xiangping Qian
Jeffrey T Finer
Pu-Ping Lu
Chihyan Grace Chuang
Bradley P Morgan
Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PE20080432A1 publication Critical patent/PE20080432A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA X, DONDE W1 ES N, CR6; W2 ES N, CR4, SIEMPRE QUE AMBOS W1 Y W2 NO SON N; R1 Y R4 SON CADA UNO H, CIANO, HALO, HIDROXI, AZIDO, ENTRE OTROS; Z1 ES H, ARILO SUSTITUIDO O NO, HETEROARILO, ENTRE OTROS; Z2 ES H, CARBOXILO, AMIDINO SUSTITUIDO O NO, ACILO, ENTRE OTROS; Z3 ES H, HALOGENO, ALQUILO SUSTITUIDO O NO; R3 ES H, ALQUILO SUSTITUIDO O NO; R6 ES H, ACILO, CIANO, HALO, AZIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-METIL-{6-FENIL-2-[(2-FENILETIL)AMINO]-(3-PIRIDIL)}CARBOXAMIDA; {2-[(3-METILBUTIL)AMINO]-6-FENIL-(3-PIRIDIL)}-N-(3-PIRIDILMETIL)CARBOXAMIDA; 2-{[(METILSULFONIL)AMINO]METIL}PIPERIDIL-6-FENIL-2-[(2-(2-PIRIDIL)ETIL)AMINO](3-PIRIDIL)CETONA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN MIOSINA DEL MUSCULO LISO Y/O MIOSINA NO MUSCULAR UTILES EN EL TRATAMIENTO DE HIPERTENSION, ASMA, GLAUCOMA, DERRAME CEREBRAL, ENTRE OTROSREFERS TO A COMPOUND OF FORMULA X, WHERE W1 IS N, CR6; W2 IS N, CR4, PROVIDED THAT BOTH W1 AND W2 ARE NOT N; R1 AND R4 ARE EACH H, CYANE, HALO, HYDROXY, AZIDO, AMONG OTHERS; Z1 IS H, ARYL, SUBSTITUTED OR NOT, HETEROARYL, AMONG OTHERS; Z2 IS H, CARBOXYL, AMIDINE SUBSTITUTED OR NOT, ACIL, AMONG OTHERS; Z3 IS H, HALOGEN, ALKYL SUBSTITUTED OR NOT; R3 IS H, RENTAL SUBSTITUTED OR NOT; R6 IS H, ACILO, CYANE, HALO, AZIDO, AMONG OTHERS. PREFERRED COMPOUNDS ARE: N-METHYL- {6-PHENYL-2 - [(2-PHENYLETHYL) AMINO] - (3-PYRIDYL)} CARBOXAMIDE; {2 - [(3-METHYLBUTYL) AMINO] -6-PHENYL- (3-PYRIDYL)} - N- (3-PYRIDYLMETHYL) CARBOXAMIDE; 2 - {[(METHYLSULFONYL) AMINO] METHYL} PIPERIDYL-6-PHENYL-2 - [(2- (2-PYRIDYL) ETHYL) AMINO] (3-PYRIDYL) KETONE; AMONG OTHERS. ALSO REFERRED TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS MODULATE SMOOTH MUSCLE MYOSIN AND / OR NON-MUSCULAR MYOSIN USEFUL IN THE TREATMENT OF HYPERTENSION, ASTHMA, GLAUCOMA, BRAIN SPILL, AMONG OTHERS

PE2007000999A 2006-08-01 2007-08-01 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PE20080432A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83490106P 2006-08-01 2006-08-01
US83518306P 2006-08-01 2006-08-01
US83490406P 2006-08-01 2006-08-01
US83501006P 2006-08-01 2006-08-01
US83490306P 2006-08-01 2006-08-01
US83523606P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20080432A1 true PE20080432A1 (en) 2008-05-29

Family

ID=38997696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000999A PE20080432A1 (en) 2006-08-01 2007-08-01 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Country Status (4)

Country Link
AR (1) AR062176A1 (en)
PE (1) PE20080432A1 (en)
TW (1) TW200823188A (en)
WO (1) WO2008016643A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5441705B2 (en) * 2007-10-15 2014-03-12 武田薬品工業株式会社 Amide compounds and uses thereof
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
HUE028082T2 (en) 2009-10-06 2016-11-28 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2015010832A1 (en) * 2013-07-22 2015-01-29 Syngenta Participations Ag Microbiocidal heterocyclic derivatives
JP2017214290A (en) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 Aromatic carboxylic acid amide compound
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
EP3570834B1 (en) 2017-01-11 2021-12-22 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
TWI721483B (en) 2018-07-13 2021-03-11 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
MX2022005445A (en) * 2019-11-06 2022-08-10 Remedy Plan Inc Cancer treatments targeting cancer stem cells.
CN111393376B (en) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 Synthetic method of 2-chloropyrimidine-4-formic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
JP2007533740A (en) * 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Amides as BACE inhibitors

Also Published As

Publication number Publication date
TW200823188A (en) 2008-06-01
WO2008016643A2 (en) 2008-02-07
WO2008016643A3 (en) 2008-06-19
AR062176A1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
PE20080432A1 (en) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
JP4663984B2 (en) Thiadiazolyl piperazine derivatives useful for the treatment or prevention of pain
TW200800899A (en) Novel compounds
MX2009004900A (en) Thiazole and oxazole-substituted arylamides.
BR122019017036B8 (en) tetrazole-substituted arylamide compounds, uses of said compounds and pharmaceutical composition
WO2008002596A3 (en) Adenosine a2a receptor antagonists
DK1716152T3 (en) Condensed heterocyclic compounds and their use as metabotropic receptor antagonists in the treatment of gastrointestinal disorders
EA200802007A1 (en) COMPOUNDS POTENTIATING AMPA RECEPTOR AND APPLICATION OF THE SPECIFIED COMPOUNDS IN MEDICINE
PL1735278T3 (en) Histamine h3 receptor agents, preparation and therapeutic uses
JP2008513498A5 (en)
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2008009413A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia.
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
BR0207526A (en) Compound, pharmaceutical composition, and methods for treating pain, migraine, depression, anxiety, schizophrenia, parkinson's disease, or stroke
MA30725B1 (en) ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators
MX2012004848A (en) Tricyclic heterocyclic compounds.
KR20120123691A (en) Pharmaceutical compositions for the treatment of pain and other indicatons
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
NO20092464L (en) Solid forms of racemic ilaprazole
KR930702334A (en) Indourea as a 5 hydroxytryptamine receptor antagonist
EA200501595A1 (en) AZABICYCLIC DERIVATIVES AS ANTAGONISTS OF MUSCARINE RECEPTOR
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
RU2450010C2 (en) SUBSTITUTED IMIDAZO{2,1-b}THIAZOLES AND APPLICATION THEREOF FOR MAKING DRUG PREPARATIONS
EA200900245A1 (en) HEMOKIN RECEPTOR ACTIVITY MODULATORS, CRYSTAL FORMS AND METHOD FOR THEIR RECEPTION

Legal Events

Date Code Title Description
FC Refusal